Aleksandra P Vidisheva1, James Wang2,3, Tanya M Spektor1, Jacob D Bitran4, Jose Lutzky5, Imad A Tabbara6, Joseph Z Ye7, Sikander Ailawadhi8, Laura V Stampleman9, Ronald G Steis10, Mehdi M Moezi11, Regina A Swift2, Tina M Maluso2, Kyle A Udd2, Shahrooz Eshaghian2, Youram Nassir2, James R Berenson12,13,14. 1. Oncotherapeutics, West Hollywood, CA, USA. 2. James R. Berenson, MD, Inc., West Hollywood, CA, USA. 3. Institute for Myeloma and Bone Cancer Research, 9201 W. Sunset Blvd., Suite 300, West Hollywood, CA, 90069, USA. 4. Oncology Specialist Research Institute, Park Ridge, IL, USA. 5. Mount Sinai Medical Center, Miami Beach, FL, USA. 6. George Washington University, Washington, DC, USA. 7. Vista Oncology, Olympia, WA, USA. 8. University of Southern California, Los Angeles, CA, USA. 9. Pacific Cancer Care, Monterey, CA, USA. 10. Atlanta Cancer Care, Atlanta, GA, USA. 11. Cancer Specialists of North Florida, Jacksonville, FL, USA. 12. Oncotherapeutics, West Hollywood, CA, USA. jberenson@imbcr.org. 13. James R. Berenson, MD, Inc., West Hollywood, CA, USA. jberenson@imbcr.org. 14. Institute for Myeloma and Bone Cancer Research, 9201 W. Sunset Blvd., Suite 300, West Hollywood, CA, 90069, USA. jberenson@imbcr.org.
Abstract
OBJECTIVE: Neuropathy is an important complication that may limit treatment options for patients with multiple myeloma. Previous studies have focused on treatment efficacy and have shown that retreatment with bortezomib (BTZ) is an effective treatment option. The goal of this study was to focus on the clinical manifestations of peripheral neuropathy (PN) and to retrospectively compare the incidence and severity of PN between the initial BTZ regimen and upon retreatment. Furthermore, this study evaluated how certain factors affect BIPN, which will help determine what conditions should be considered prior to retreatment. METHODS: Charts were reviewed from 93 patients who were retreated with a BTZ-containing regimen after previously being treated with this drug. RESULTS: Among the patients who developed PN, most patients in the study had low-grade neuropathy during the initial BTZ treatment (n = 52, 68%). The results showed no evidence of cumulative toxicity, and there was no significant difference in the incidence and severity of PN upon retreatment. Factors such as the presence of baseline PN, number of prior treatments, dose of BTZ, and comorbidities did not increase the severity of PN upon retreatment. The lapse of time between the two regimens also did not affect the severity of PN. CONCLUSION: The results suggest that retreatment with BTZ may be a feasible option, without additional risks of PN, for MM patients even with peripheral neuropathy during their initial treatment with this drug.
OBJECTIVE:Neuropathy is an important complication that may limit treatment options for patients with multiple myeloma. Previous studies have focused on treatment efficacy and have shown that retreatment with bortezomib (BTZ) is an effective treatment option. The goal of this study was to focus on the clinical manifestations of peripheral neuropathy (PN) and to retrospectively compare the incidence and severity of PN between the initial BTZ regimen and upon retreatment. Furthermore, this study evaluated how certain factors affect BIPN, which will help determine what conditions should be considered prior to retreatment. METHODS: Charts were reviewed from 93 patients who were retreated with a BTZ-containing regimen after previously being treated with this drug. RESULTS: Among the patients who developed PN, most patients in the study had low-grade neuropathy during the initial BTZ treatment (n = 52, 68%). The results showed no evidence of cumulative toxicity, and there was no significant difference in the incidence and severity of PN upon retreatment. Factors such as the presence of baseline PN, number of prior treatments, dose of BTZ, and comorbidities did not increase the severity of PN upon retreatment. The lapse of time between the two regimens also did not affect the severity of PN. CONCLUSION: The results suggest that retreatment with BTZ may be a feasible option, without additional risks of PN, for MMpatients even with peripheral neuropathy during their initial treatment with this drug.
Authors: Paul G Richardson; Hannah Briemberg; Sundar Jagannath; Patrick Y Wen; Bart Barlogie; James Berenson; Seema Singhal; David S Siegel; David Irwin; Michael Schuster; Gordan Srkalovic; Raymond Alexanian; S Vincent Rajkumar; Steven Limentani; Melissa Alsina; Robert Z Orlowski; Kevin Najarian; Dixie Esseltine; Kenneth C Anderson; Anthony A Amato Journal: J Clin Oncol Date: 2006-06-05 Impact factor: 44.544
Authors: James R Berenson; Sundar Jagannath; Bart Barlogie; David T Siegel; Raymond Alexanian; Paul G Richardson; David Irwin; Melissa Alsina; S Vincent Rajkumar; Gordon Srkalovic; Seema Singhal; Steven Limentani; Ruben Niesvizky; Dixie L Esseltine; Elizabeth Trehu; David P Schenkein; Kenneth Anderson Journal: Cancer Date: 2005-11-15 Impact factor: 6.860
Authors: T Hideshima; P Richardson; D Chauhan; V J Palombella; P J Elliott; J Adams; K C Anderson Journal: Cancer Res Date: 2001-04-01 Impact factor: 12.701
Authors: Steffan T Nawrocki; Jennifer S Carew; Kenneth Dunner; Lawrence H Boise; Paul J Chiao; Peng Huang; James L Abbruzzese; David J McConkey Journal: Cancer Res Date: 2005-12-15 Impact factor: 12.701
Authors: Ashraf Badros; Olga Goloubeva; Jay S Dalal; Ilyas Can; Jennifer Thompson; Aaron P Rapoport; Meyer Heyman; Gorgon Akpek; Robert G Fenton Journal: Cancer Date: 2007-09-01 Impact factor: 6.860